Low Bilirubin Predicts Cardiac Risk in Metabolic Syndrome

This article originally appeared here.
Share this content:
Low Bilirubin Predicts Cardiac Risk in Metabolic Syndrome
Low Bilirubin Predicts Cardiac Risk in Metabolic Syndrome

(HealthDay News) -- Low serum total bilirubin levels may improve risk prediction of coronary artery disease (CAD) in patients with metabolic syndrome, according to research published in the Dec. 1 issue of The American Journal of Cardiology.

Young Shin Song, M.D., of Seoul National University in South Korea, and colleagues examined CAD events over four years according to baseline serum bilirubin levels in a prospective cohort of 8,593 Korean community members.

The researchers found that 0.9 percent of the cohort developed CAD events during follow-up. The lowest serum total bilirubin level (≤0.32 mg/dL) was independently associated with higher risk of future CAD events (adjusted hazard ratio [HR], 1.890; P = 0.024). Compared with individuals without metabolic syndrome, those with metabolic syndrome were more likely to have future CAD events (HR, 3.366; P < 0.001). Individuals with metabolic syndrome who had low bilirubin levels were six times more likely to have CAD events (HR, 6.228; P < 0.001) than those who did not have metabolic syndrome or low bilirubin levels.

"In conclusion, the addition of low serum bilirubin levels to the traditional risk factors for CAD, such as metabolic syndrome, may yield an improvement of risk prediction," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Many Foster Kids Inappropriately Prescribed Psychiatric Drugs

Many Foster Kids Inappropriately Prescribed Psychiatric Drugs

Some children may be getting meds they don't need, others may be going without drugs that may help

FDA Approves Device for Acute Coronary Artery Perforations

FDA Approves Device for Acute Coronary Artery Perforations

The PK Papyrus device is a balloon-expandable covered coronary stent and delivery system

Decrease in Infant Walker-Related Injuries Since 2010

Decrease in Infant Walker-Related Injuries Since 2010

Decrease in injuries following implementation of federal mandatory safety standard in 2010

is free, fast, and customized just for you!




Already a member?

Sign In Now »